 Cellectar Biosciences Inc NASDAQ: CLRB announced updated data at the American Society of Clinical Oncology ASCO Annual Meeting from Phase 2 CLOVER-1 study of CLR 131 in relapsedrefractory B-cell hematologic cancers. Data from 131 Waldenstroms macroglobulinemia WM patients showed a 100 66 overall response rate, 83.3 major response rate, and a 16.7 complete response rate. 